Substance / Medication

Temsirolimus

SNOMED 427153004 UMLS C1707080

Overview

Active Ingredient

temsirolimus

RxNorm CUI

657797

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Renal cell carcinoma

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

NCT01180049Phase 4Completed101 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.

Garcia Christine A, Wu Shenhong · Cancer Invest · 2016

PMID: 27791402Meta-Analysis

Peng Ling, Zhou Yun, Ye Xianghua et al. · Tumour Biol · 2015

PMID: 25281033Meta-Analysis

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.

Abdel-Rahman Omar, Fouad Mona · Expert Rev Anticancer Ther · 2015

PMID: 25994247Meta-Analysis

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.

Xu Jian, Tian Deying · Curr Med Res Opin · 2014

PMID: 24028709Meta-Analysis

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.

Qi Wei-Xiang, Huang Yu-Jing, Yao Yang et al. · PLoS One · 2013

PMID: 23785409Meta-AnalysisFull text (PMC)

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.

Gomez-Fernandez Cristina, Garden Benjamin C, Wu Shenwong et al. · Eur J Cancer · 2012

PMID: 22206873Meta-Analysis

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Thompson Coon J, Hoyle M, Green C et al. · Health Technol Assess · 2010

PMID: 20028613Meta-Analysis

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

Bhojani Naeem, Jeldres Claudio, Patard Jean-Jacques et al. · Eur Urol · 2008

PMID: 18054825Meta-Analysis

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.

Boni Joseph P, Leister Cathie, Hug Bruce et al. · Cancer Chemother Pharmacol · 2012

PMID: 22367193RCT

Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.

Lunardi Gianluigi, Armirotti Andrea, Nicodemo Maurizio et al. · Clin Ther · 2009

PMID: 19808140RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Temsirolimus (substance)
SNOMED CT: 427153004
UMLS CUI: C1707080
RxNorm CUI: 657797

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.